

Edgar Filing: VASOMEDICAL INC - Form 8-K

VASOMEDICAL INC  
Form 8-K  
January 26, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report: January 26, 2005  
(Date of earliest event reported)

VASOMEDICAL, INC.  
(Exact name of registrant as specified in its charter)

Delaware	0-18105	11-2871434
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
180 Linden Avenue, Westbury, New York		11590
-----		-----
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number including area code		(516) 997-4600
		-----

Not applicable  
-----

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR  
230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act

Pre-commencement communications pursuant to Rule 13e-4c under the Exchange  
Act (17 CFR 240.13e-4c)

INFORMATION TO BE INCLUDED IN THE REPORT

## Edgar Filing: VASOMEDICAL INC - Form 8-K

The information in this Form 8-K Current Report and the exhibit attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

### Item 8.01 Other Events

The Company has been informed that at the American College of Cardiology's session entitled "Late-Breaking Clinical Trials: Mechanisms and New Therapeutic Approaches", to be held on March 8, 2005 at 4:15 p.m. in Orlando, Florida, a presentation will be made with respect to the Company's PEECH Clinical Study. The presentation is entitled "Prospective Evaluation of EECF in Congestive Heart Failure."

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VASOMEDICAL, INC.

/s/Thomas W. Fry

-----  
Thomas W. Fry  
Chief Financial Officer  
(Principal Financial and Accounting  
Officer)

Dated: January 26, 2005